Allakos Gets $32M For Antibody Therapeutics

San Mateo-based Allakos said today that it has raised $32M in a Series A financing round, which will go towards its antibody therapeutics for treating allergic and inflammatory diseases. The funding was led by Novo Ventures, and also included Alta Partners, RiverVest Venture Partners and the Roche Venture Fund. The company has added Peter Moldt of Novo Ventures, Robert Alexander of Alta Partners, and John McKearn at Rivervest to its board. More information »